bibliographicCitation |
Xue Y, Yang L, Li J, Yan Y, Jiang Q, Shen L, Yang S, Shen B, Huang R, Yan J, Guo H. Combination chemotherapy with Zyflamend reduced the acquired resistance of bladder cancer cells to cisplatin through inhibiting NFκB signaling pathway. Onco Targets Ther. 2018;11():4413–29. PMID: 30104883; PMCID: PMC6072829. |